New AMD Treatments: Syfovre, Izervay and Emerging Therapies
Understanding Geographic Atrophy and Why New Treatments Matter
Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over 50, and it comes in two forms: wet and dry. While effective injectable treatments for wet AMD have been available for nearly two decades, the advanced form of dry AMD, known as geographic atrophy (GA), had no approved treatment until recently. Geographic atrophy causes a gradual and irreversible loss of retinal cells in the macula, slowly expanding the areas of vision loss over time. The recent approval of two new medications represents a major milestone for the millions of patients living with this condition.
For years, patients with geographic atrophy were told that no treatment existed to slow the progression of their disease. Nutritional supplements such as the AREDS2 formula could help reduce the risk of progressing to advanced AMD, but once geographic atrophy developed, there was little that could be done beyond monitoring. That changed in 2023 with the FDA approval of two complement inhibitor therapies that target a key part of the immune pathway involved in retinal cell destruction.
Geographic atrophy is the advanced stage of dry age-related macular degeneration. It occurs when clusters of light-sensing cells (photoreceptors) and the supportive tissue beneath them (retinal pigment epithelium) gradually break down and die. This creates expanding patches of cell loss in the macula that correspond to blind spots in your central vision. The progression is typically slow, occurring over months to years, but it can eventually cause significant difficulty with reading, recognizing faces, and driving.
Research has shown that the complement system, a part of your body's immune defense, plays a central role in driving geographic atrophy. In a healthy eye, the complement system helps clear damaged cells and fight infection. In patients with GA, this system becomes overactive and begins attacking healthy retinal tissue. Both Syfovre and Izervay work by inhibiting specific proteins in the complement cascade to reduce this destructive process and slow the growth of atrophic lesions.
Patients diagnosed with geographic atrophy in one or both eyes may be candidates for these new therapies. Your retina specialist will use advanced imaging, including optical coherence tomography (OCT) and fundus autofluorescence, to measure the size and location of your GA lesions and determine whether treatment is appropriate. Factors such as the proximity of the atrophy to your central vision, the rate of progression, and your overall eye health all play a role in deciding if and when to begin therapy.
Even with new treatments available, early detection of AMD remains critical. These therapies are designed to slow the growth of geographic atrophy, not reverse damage that has already occurred. The sooner GA is identified and treatment is started, the more healthy retinal tissue can potentially be preserved. Regular comprehensive eye exams and prompt evaluation of any new changes in your vision give you the best chance of maintaining functional sight for as long as possible.
Syfovre and Izervay: How These Treatments Work
Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) are both intravitreal injections, meaning they are delivered directly into the eye in a brief office procedure similar to the injections used for wet AMD. While they share the same general goal of slowing geographic atrophy progression, they target different points in the complement pathway. Understanding the differences between these two medications can help you have a more informed conversation with your retina specialist about which option may be right for you.
Syfovre was the first FDA-approved treatment for geographic atrophy, receiving approval in February 2023, followed by Izervay in August 2023. Clinical trials for both medications demonstrated a meaningful reduction in the rate of GA lesion growth compared to observation alone. Neither drug restores vision that has already been lost, but by slowing the expansion of atrophy, they aim to preserve remaining vision and delay further decline.
Syfovre is a complement C3 inhibitor, meaning it blocks the complement cascade at an early and central point in the pathway. It was studied in the OAKS and DERBY clinical trials, which showed that monthly and every-other-month injections significantly reduced the growth rate of GA lesions over two years. Syfovre can be administered monthly or every other month depending on the treatment plan your doctor recommends. It is currently the only approved GA therapy that targets complement factor C3.
Izervay is a complement C5 inhibitor that blocks the pathway at a later stage than Syfovre. It was studied in the GATHER1 and GATHER2 clinical trials, which demonstrated a significant slowing of GA progression with monthly injections over 12 months. Izervay is administered as a monthly intravitreal injection. By targeting C5, it aims to reduce the formation of the membrane attack complex, which is directly involved in destroying retinal cells.
Both treatments are given as injections in the eye during a short office visit. Your doctor will numb the eye with anesthetic drops, clean the area to minimize infection risk, and administer the injection using a very fine needle. The procedure typically takes only a few minutes, and most patients experience minimal discomfort. You will need to return for repeat injections on a regular schedule, either monthly or every other month depending on the medication, so consistency with your treatment plan is important for achieving the best results.
As with any eye injection, both Syfovre and Izervay carry some risks. The most common side effects include mild eye discomfort, small hemorrhages on the surface of the eye, and temporary blurry vision after the injection. A more serious but less common concern with both treatments is a slightly increased risk of developing wet AMD or eye inflammation (endophthalmitis). Your retina specialist will monitor you closely at each visit with imaging to check for any signs of complications and will discuss the risk-benefit profile with you before starting treatment.
Emerging Therapies and the Future of Dry AMD Treatment
While Syfovre and Izervay represent important first steps, researchers and pharmaceutical companies are actively pursuing the next generation of treatments for geographic atrophy and dry AMD. These emerging therapies aim to offer improved efficacy, longer intervals between treatments, and new mechanisms of action that could complement or even surpass current options. The pace of innovation in this field has accelerated dramatically, and several promising candidates are in various stages of clinical development.
Many of the therapies in the pipeline focus on alternative targets within the complement system, neuroprotection to prevent retinal cell death, or even regenerative approaches that could one day restore lost vision. Gene therapy and sustained-release drug delivery systems are also being explored as ways to reduce the treatment burden on patients who currently require frequent office visits for injections. While these therapies are still being studied, they offer genuine hope that the treatment landscape for dry AMD will continue to improve in the coming years.
One of the biggest challenges with current GA treatments is the need for frequent injections. Researchers are developing sustained-release implants and depot formulations that could deliver medication inside the eye for months at a time, reducing the number of office visits required. Port delivery systems, biodegradable implants, and slow-release microspheres are among the technologies being studied to make treatment more convenient while maintaining effectiveness.
Gene therapy holds the potential to provide a one-time treatment that enables the eye to produce its own protective proteins on an ongoing basis. Several clinical trials are investigating gene therapies that deliver complement-regulating genes directly into retinal cells. If successful, these approaches could offer long-term protection against geographic atrophy without the need for repeated injections, fundamentally changing how dry AMD is managed.
Beyond targeting the complement system, some researchers are exploring therapies that protect retinal cells from dying or even replace cells that have already been lost. Neuroprotective agents aim to shield photoreceptors and retinal pigment epithelium from the degenerative process. Stem cell therapies, while still in early stages, are being studied as a way to transplant healthy retinal cells into areas damaged by geographic atrophy, with the goal of restoring some degree of visual function.
If you have been diagnosed with geographic atrophy, there is more reason for optimism now than at any point in the past. Two FDA-approved treatments are currently available, and a robust pipeline of emerging therapies is moving through clinical trials. The most important step you can take is to maintain regular appointments with your retina specialist, stay current with recommended imaging, and discuss whether starting treatment now could help preserve your remaining vision. As the science continues to advance, your doctor can help you evaluate new options as they become available.
What our Patients say
4.8
Reviews
(3645)